Geoffrey Oxnard is an Oncology physician affiliated with Boston Medical Center. OpenAlex indexes 1,017 publications with 29,483 citations (h-index 77); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
830 Harrison Avenue, 3rd Fl
Moakley Bldg
Boston, MA 02118
Telephone
617-638-6428Provider last certified this registry record 20 May 2026.
Clinical trials
- Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance
Sponsor: Addario Lung Cancer Medical Institute
- Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Sponsor: Dana-Farber Cancer Institute
- Sunitinib in Never-Smokers With Lung Adenocarcinoma
Sponsor: Dana-Farber Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor100%Tagrisso100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2019–2019 per NIH RePORTER. The latest:
- Study of Plasma Next Generation Sequencing for Remote Assessment, Characterization, Evaluation of Patients with ALK Drug Resistance (SPACEWALK)
Dana-Farber Cancer Inst
FY2019$230,333R21CA234816
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Alice Jacobs, MD
Boston Medical Center
Carlos Kase, MD
Boston Medical Center
Sushrut Waikar, MD
Boston Medical Center
Darae Ko, MD
Boston Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”